UPDRS benefit from dual frequency DBS fields sculpted by intentionally overlapped interleaving
Objective: We show that UPDRS-III scores after interleaving compared to those prior to interleaving reflect a gain in benefit by lowered scores. Background: Previously, we…Factors determining the motor outcome of STN DBS in PD patients: Evidence for Dual Actions
Objective: We investigated factors determining the motor outcome of STN DBS in patients with Parkinson disease (PD). Background: The STN DBS has revolutionized the management…Baseline characteristics associated with greatest improvement in HRQL after DBS surgery
Objective: To determine the characteristics of DBS candidates associated with the greatest improvement in HRQL outcomes after surgery. Background: Site reviews of expert DBS centers…Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease
Objective: To examine the impact of Nurr1 agonists on regulation of striatal Nurr1 and levodopa (LD)-induced dyskinesias (LIDs) in a rat model of Parkinson’s disease…Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Tardive Dyskinesia
Objective: To evaluate the efficacy, safety, and tolerability of deutetrabenazine in patients with tardive dyskinesia (TD). Background: AIM-TD is the second large 12-week, Phase III,…Improving Nursing Education on the care of those with Parkinson’s disease
Objective: The Edmond J. Safra Visiting Nurse Faculty Program at the Parkinson's DIsease Foundation provides a 40 contact hour accredited course for nursing faculty by linking…Ataxia and increased cerebrospinal fluid phosphate associated with a mutation in the SLC20A2 gene
Objective: To characterize the phenotype and biochemical abnormalities associated with the R467X mutation in the SLCA20A2 gene. Background: Mutations in the SLC20A2 gene are the…Huntington’s Disease Regulatory Science Consortium (HD-RSC): Enabling Pathways to Effective Treatments Through Regulatory Science and Innovation
Objective: To establish a broad-based consortium, the Huntington’s Disease Regulatory Science Consortium (HD-RSC), which will advance disease specific data standards and drug development tools, as…Imaging of phosphodiesterase 10 A (PDE10A) enzyme levels in the living human brain of Huntington’s disease gene expansion carriers and healthy controls with positron emission tomography.
Objective: The objective of this study was to examine the loss of Phosphodiesterase 10A enzyme (PDE10A) across a broad spectrum of Huntington’s disease (HD) stages.…Depression among Inpatients with Huntington’s Disease: Patient Characteristics and Outcomes
Objective: To better understand the relationship between Huntington’s Disease and depression. Background: Huntington’s Disease (HD) is an uncommon genetic neurodegenerative disorder in the United States…
- « Previous Page
- 1
- …
- 72
- 73
- 74
- 75
- 76
- …
- 155
- Next Page »